Home
/
Nuo Therapeutics, Inc.
/
Financials
/
Quarterly
Nuo Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Nuo Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$162.2K
Nov 13, 2017
Q2
2017
Jun 30, 2017
$188.6K
Aug 14, 2017
Q1
2017
Mar 31, 2017
$172.7K
May 15, 2017
Q3
2017
Sep 30, 2016
$176.8K
Nov 13, 2017
Q2
2017
Jun 30, 2016
$134.9K
Aug 14, 2017
Q1
2016
Mar 31, 2016
$1.41M
Oct 24, 2016
Q3
2015
Sep 30, 2015
$2.17M
Nov 13, 2015
Q2
2015
Jun 30, 2015
$2.90M
Aug 13, 2015
Q1
2016
Mar 31, 2015
$4.84M
Oct 24, 2016
Q3
2015
Sep 30, 2014
$1.69M
Nov 13, 2015
Q2
2015
Jun 30, 2014
$2.33M
Aug 13, 2015
Q1
2015
Mar 31, 2014
$1.85M
May 14, 2015
Q3
2013
Sep 30, 2013
$3.37M
Nov 12, 2013
Q2
2014
Jun 30, 2013
$2.42M
Aug 14, 2014
Q1
2014
Mar 31, 2013
$2.32M
May 15, 2014
Q3
2013
Sep 30, 2012
$1.76M
Nov 12, 2013
Q2
2013
Jun 30, 2012
$3.69M
Aug 8, 2013
Q1
2013
Mar 31, 2012
$3.02M
May 9, 2013
Q3
2012
Sep 30, 2011
$1.53M
Nov 14, 2012
Q2
2012
Jun 30, 2011
$1.39M
Aug 14, 2012
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2014
Sep 30, 2014
$1.69M
Nov 13, 2014
Q2
2014
Jun 30, 2014
$1.85M
Aug 14, 2014
Q1
2014
Mar 31, 2014
$1.42M
May 15, 2014
Q3
2014
Sep 30, 2013
$3.37M
Nov 13, 2014
Q2
2014
Jun 30, 2013
$2.36M
Aug 14, 2014
Q1
2014
Mar 31, 2013
$2.25M
May 15, 2014
Q3
2013
Sep 30, 2012
$1.70M
Nov 12, 2013
Q2
2015
Jun 30, 2012
$10.00M
Aug 13, 2015
Q1
2015
Jun 30, 2012
$10.00M
May 14, 2015
Q3
2015
Jun 30, 2012
$10.00M
Nov 13, 2015
Q1
2013
Mar 31, 2012
$1.69M
May 9, 2013
Q3
2012
Sep 30, 2011
$1.53M
Nov 14, 2012
Q2
2012
Jun 30, 2011
$1.39M
Aug 14, 2012
Q1
2012
Mar 31, 2011
$1.37M
May 15, 2012
Q3
2011
Sep 30, 2010
$1.29M
Nov 14, 2011
Q2
2011
Jun 30, 2010
$1.15M
Aug 15, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($537.9K)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($649.7K)
Jul 31, 2025
Q3
2025
Jun 30, 2025
($649.7K)
Oct 30, 2025
Q3
2025
Mar 31, 2025
($746.1K)
Oct 30, 2025
Q1
2025
Mar 31, 2025
($746.1K)
Apr 30, 2025
Q2
2025
Mar 31, 2025
($746.1K)
Jul 31, 2025
Q3
2025
Sep 30, 2024
($578.2K)
Oct 30, 2025
Q3
2025
Jun 30, 2024
($540.1K)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($540.1K)
Jul 31, 2025
Q2
2025
Mar 31, 2024
($708.8K)
Jul 31, 2025
Q3
2025
Mar 31, 2024
($708.8K)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($708.8K)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($790.6K)
Nov 12, 2024
Q3
2024
Jun 30, 2023
($871.9K)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($871.9K)
Aug 12, 2024
Q2
2024
Mar 31, 2023
($855.8K)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($855.8K)
May 15, 2024
Q3
2024
Mar 31, 2023
($855.8K)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($912.8K)
Nov 20, 2023
Q3
2023
Jun 30, 2022
($924.1K)
Nov 20, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($540.1K)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($652.0K)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($745.1K)
Apr 30, 2025
Q3
2025
Sep 30, 2024
($577.4K)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($542.0K)
Jul 31, 2025
Q1
2025
Mar 31, 2024
($709.2K)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($789.6K)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($871.4K)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($855.2K)
May 15, 2024
Q3
2023
Sep 30, 2022
($911.9K)
Nov 20, 2023
Q2
2023
Jun 30, 2022
($923.7K)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($521.8K)
May 15, 2023
Q3
2022
Sep 30, 2021
($6.8K)
Nov 4, 2022
Q2
2022
Jun 30, 2021
($6.5K)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($5.7K)
May 16, 2022
Q3
2021
Sep 30, 2020
($6.3K)
Nov 4, 2022
Q3
2019
Sep 30, 2019
($38.7K)
Jan 31, 2020
Q2
2019
Jun 30, 2019
($392.4K)
Aug 19, 2019
Q1
2019
Mar 31, 2019
($611.8K)
May 20, 2019
Q3
2019
Sep 30, 2018
($411.8K)
Jan 31, 2020